Clinical Trials Directory

Trials / Sponsors / Allergy Therapeutics

Allergy Therapeutics

Industry · 27 registered clinical trials1 currently recruiting.

StatusTrialPhaseStarted
RecruitingGRASS (Grass MATA MPL Real-world Assessment Study)
Grass Pollen Allergy
2026-03-11
Active Not RecruitingPhase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects
Peanut Allergy
Phase 12022-10-17
CompletedEfficacy and Safety of PQ Grass in Subjects With Seasonal Allergic Rhinitis and/or Rhinoconjunctivitis Induced
Seasonal Allergic Rhinitis, Rhinoconjunctivitis
Phase 32022-10-11
CompletedEffect of holoBLG on Cat Allergic Patients
Allergy to Cats, Allergic Rhinoconjunctivitis
N/A2021-10-04
Active Not RecruitingTyrosine Allergoid Paediatric and Adult Study
Allergic Rhinitis Due to Pollen, Allergic Conjunctivitis, Allergic Asthma
2020-11-06
CompletedAn Exploratory Study of PQ Grass 27600 SU
Rhinitis, Allergic, Seasonal
Phase 2 / Phase 32020-10-19
CompletedInfluence of Specific Immunotherapy With Pollinex Quattro (Tree-/Grass Pollen) on Allergen-specific Immunoglob
Rhinitis, Allergic, Respiratory Tract Infections, Allergy
2020-04-22
CompletedA Study of Tolerability and Safety of a New Cumulative Dose of Grass MATA MPL
Seasonal Allergic Rhinitis
Phase 12017-01-16
CompletedDose Selection Study of Efficacy and Safety of Different Doses of Grass MATA MPL and Grass MATA Using mEECs™
Seasonal Allergic Rhinitis
Phase 22015-11-07
CompletedA Study of Tolerability and Safety of Two New Doses of Grass MATA MPL
Allergic Rhinitis
Phase 12015-08-01
CompletedEfficacy and Safety/Tolerability of Ragweed MATA MPL
Type I Hypersensitivity
Phase 32007-03-01
CompletedEfficacy and Safety/Tolerability of Grass MATA MPL
Type I Hypersensitivity
Phase 32006-11-01
TerminatedInvestigation of Efficacy and Safety of Tree MATAMPL,Tree MATA, and Placebo in Patients With Birch-Induced Sea
Type I Hypersensitivity
Phase 22006-10-01
CompletedFollow-up Investigation of Efficacy of Ragweed MATAMPL,and Placebo in Patients With Ragweed-induced Seasonal A
Type I Hypersensitivity
Phase 22006-05-01
CompletedSafety, Immunological Effect and Efficacy of the Combined Application of MPL and Grass Pollen Allergen
Type I Hypersensitivity
Phase 12005-12-01
CompletedInvestigation of Safety+Efficacy of Different Doses of RagweedMATAMPL;Assessment of Residual Allergenicity Usi
Type I Hypersensitivity
Phase 22005-11-01
CompletedDifferent Doses of Tyrosine Adsorbed Grass Pollen Allergoid With Monophosphoryl Lipid A (MPL) in Patients Sens
Type I Hypersensitivity
Phase 22005-09-12
CompletedAssessment of the Contribution of Monophosphoryl Lipid A (MPL) to a Grass Pollen Allergy Vaccine
Type I Hypersensitivity
Phase 22005-09-12
CompletedDifferent Doses of Tyrosine Adsorbed Tree Pollen Allergoid With Monophosphoryl Lipid A (MPL) in Patients Sensi
Type I Hypersensitivity
Phase 22005-07-07
CompletedAssessment of the Contribution of Monophosphoryl Lipid A (MPL) to a Tree Pollen Allergy Vaccine
Type I Hypersensitivity
Phase 22005-07-01
CompletedInduction of Immunogenicity With Different Doses of TreeMATA in Subjects Allergic to Tree Pollen
Type I Hypersensitivity
Phase 22005-07-01
CompletedAssessment of Residual Allergenicity of Ragweed Pollen Allergoid With Monophosphoryl Lipid A (MPL) Using Skin
Type I Hypersensitivity
Phase 12005-06-01
CompletedInvestigation of Efficacy and Safety of Ragweed MATAMPL, Pollinex-R and Placebo in Patients With Ragweed Aller
Type I Hypersensitivity
Phase 22005-05-01
WithdrawnEvaluation of Safety and Tolerability of Tyrosine Adsorbed Ragweed Pollen Allergoid With MPL (Monophosphoryl L
Type I Hypersensitivity
Phase 12005-05-01
CompletedAssessment of Residual Allergenicity of Tree (Birch, Hazel, and Alder) Pollen Allergoid Using Skin Prick Testi
Type I Hypersensitivity
Phase 12005-04-01
CompletedAssessment of Residual Allergenicity of Grass/Rye Pollen Allergoid Using Skin Prick Testing
Type I Hypersensitivity
Phase 12005-03-01
CompletedInduction of Immunogenicity With Different Doses of Grass MATA in Subjects Allergic to Grass and Rye Pollen
Type I Hypersensitivity
Phase 22005-03-01